Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of PARP and Immune-Checkpoint Inhibitor Combinations
Ross Stewart, Patrick G. Pilié, Timothy A. Yap
Cancer Research (2018) Vol. 78, Iss. 24, pp. 6717-6725
Open Access | Times Cited: 189

Showing 1-25 of 189 citing articles:

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Ming Yi, Xiaoli Zheng, Mengke Niu, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 852
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma, Bilal A. Siddiqui, Swetha Anandhan, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 838-857
Open Access | Times Cited: 544
Poly(ADP-ribose) polymerase inhibition: past, present and future
Nicola J. Curtin, Csaba Szabó
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 10, pp. 711-736
Closed Access | Times Cited: 403
Development of Immunotherapy Combination Strategies in Cancer
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, et al.
Cancer Discovery (2021) Vol. 11, Iss. 6, pp. 1368-1397
Open Access | Times Cited: 237
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
Lena Horvath, Bernard Thienpont, Liyun Zhao, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 198
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud, Antoîne Italiano
Cancers (2020) Vol. 12, Iss. 6, pp. 1502-1502
Open Access | Times Cited: 181
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Anish Thomas, Rasa Vilimas, Christopher Trindade, et al.
Journal of Thoracic Oncology (2019) Vol. 14, Iss. 8, pp. 1447-1457
Open Access | Times Cited: 163
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Timothy A. Yap, Ruth Plummer, Nilofer S. Azad, et al.
American Society of Clinical Oncology Educational Book (2019), Iss. 39, pp. 185-195
Closed Access | Times Cited: 157
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Amy L. Shergold, Rhona Millar, Robert J. B. Nibbs
Pharmacological Research (2019) Vol. 145, pp. 104258-104258
Open Access | Times Cited: 146
Ovarian Cancer Immunotherapy: Turning up the Heat
Eleonora Ghisoni, Martina Imbimbo, Stefan Zimmermann, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 12, pp. 2927-2927
Open Access | Times Cited: 145
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 3, pp. 283-299
Open Access | Times Cited: 135
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0
Egesta Lopci, Rodney J. Hicks, Antonia Dimitrakopoulou‐Strauss, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 49, Iss. 7, pp. 2323-2341
Open Access | Times Cited: 78
PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
Dongha Kim, Hye Jin Nam
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8412-8412
Open Access | Times Cited: 71
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 17
Prospects for combining immune checkpoint blockade with PARP inhibition
Anping Li, Ming Yi, Shuang Qin, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 120
Advances and perspectives of PARP inhibitors
Ming Yi, Bing Dong, Shuang Qin, et al.
Experimental Hematology and Oncology (2019) Vol. 8, Iss. 1
Open Access | Times Cited: 103
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy
Sonia Iyer, Shuang Zhang, Simge Yucel, et al.
Cancer Discovery (2020) Vol. 11, Iss. 2, pp. 384-407
Open Access | Times Cited: 98
Leveraging NKG2D Ligands in Immuno-Oncology
Mercedes B. Fuertes, Carolina I. Domaica, Norberto W. Zwirner
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 94
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
Dean A. Fennell, Amy King, Seid Mohammed, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 6, pp. 593-600
Closed Access | Times Cited: 91
DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes
Thiago Vidotto, Sarah Nersesian, Charles H. Graham, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 81
PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCA
Emily N. Risdon, Cindy H. Chau, Douglas K. Price, et al.
The Oncologist (2020) Vol. 26, Iss. 1, pp. e115-e129
Open Access | Times Cited: 80
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
Seung Tae Kim, Simon A. Smith, Peter G. Mortimer, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 17, pp. 4700-4709
Open Access | Times Cited: 65
Recent Advances and Challenges in Uveal Melanoma Immunotherapy
Yihang Fu, Wei Xiao, Yuxiang Mao
Cancers (2022) Vol. 14, Iss. 13, pp. 3094-3094
Open Access | Times Cited: 43
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Congqi Shi, Kaiyu Qin, Anqi Lin, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 43
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
Jing Ye, Junhao Wu, Bo Liu
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188866-188866
Closed Access | Times Cited: 27
Page 1 - Next Page

Scroll to top